AR083377A1 - Agonistas gpr 119 (receptores acoplados a la proteina g) - Google Patents
Agonistas gpr 119 (receptores acoplados a la proteina g)Info
- Publication number
- AR083377A1 AR083377A1 ARP110103746A ARP110103746A AR083377A1 AR 083377 A1 AR083377 A1 AR 083377A1 AR P110103746 A ARP110103746 A AR P110103746A AR P110103746 A ARP110103746 A AR P110103746A AR 083377 A1 AR083377 A1 AR 083377A1
- Authority
- AR
- Argentina
- Prior art keywords
- branched
- alkyl
- linear
- heterocyclyl
- heteroaryl
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- -1 nitro, formyl Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
Abstract
Las composiciones farmacéuticas que los contienen, los métodos para su preparación, el uso de estos compuestos en medicina como agente reductor de glucosa y los intermediarios involucrados en su preparación.Reivindicación 1: Compuestos de la fórmula general (1), caracterizados porque sus formas tautoméricas, sus estereoisómeros, sus sales farmacéuticamente aceptables y las composiciones farmacéuticas que los contienen, en donde R1 representa H, opcionalmente grupos sustituidos seleccionados de alquilo C1-6 lineal o ramificado, haloalquilo, alquenilo C1-6, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, aralquilo, heteroarilo, heteroarilalquilo, alquilsulfonilo, arilsulfonilo, o los grupos representados por (CH2)mCO2R4, (CH2)mCOR4 o (CH2)mCONH2 en donde R4 en cada aparición representa independientemente H, grupos seleccionados de alquilo C1-6 lineal o ramificado, cicloalquilo, arilo, heterociclilo o heteroarilo y m = 0 a 3; R2 representa H, grupos ciano, nitro, formilo, alquilo C1-6 lineal o ramificado, alcoxi C1-6; R3 representa grupos opcionalmente sustituidos seleccionados de alquilo C1-6 lineal o ramificado, arilo, aralquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, heteroarilo, heteroaralquilo o los grupos representados por C(O)OR5, C(O)R5, y SO2R5 en donde R5 en cada aparición representa independientemente H o grupos opcionalmente sustituidos seleccionados de alquilo C1-6 lineal o ramificado, grupos arilo, aralquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, heteroarilo, heteroaralquilo; n representa un entero de 0 a 3; A representa el resto de fórmula (2) en donde p representa enteros de 1 a 3; X representa O, S.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2803MU2010 | 2010-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083377A1 true AR083377A1 (es) | 2013-02-21 |
Family
ID=45464048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103746A AR083377A1 (es) | 2010-10-08 | 2011-10-11 | Agonistas gpr 119 (receptores acoplados a la proteina g) |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8785463B2 (es) |
| EP (1) | EP2625177B1 (es) |
| JP (1) | JP5814377B2 (es) |
| KR (1) | KR101563793B1 (es) |
| AP (1) | AP2013006812A0 (es) |
| AR (1) | AR083377A1 (es) |
| AU (1) | AU2011311183B2 (es) |
| BR (1) | BR112013007904A2 (es) |
| DK (1) | DK2625177T3 (es) |
| EA (1) | EA022501B1 (es) |
| ES (1) | ES2551183T3 (es) |
| HK (1) | HK1185875A1 (es) |
| MX (1) | MX2013003736A (es) |
| NZ (1) | NZ608708A (es) |
| PL (1) | PL2625177T3 (es) |
| SG (1) | SG188547A1 (es) |
| WO (1) | WO2012046249A1 (es) |
| ZA (1) | ZA201302249B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA031618B1 (ru) | 2011-06-09 | 2019-01-31 | Ризен Фармасьютикалз Са | Соединения-модуляторы gpr-119 |
| EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| US8207147B2 (en) | 2003-12-24 | 2012-06-26 | Prosidion Limited | Heterocyclic derivatives as GPCR receptor agonists |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
| EP1907384A2 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
| AU2006264651A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | G-protein coupled receptor agonists |
| US20090149508A1 (en) | 2005-07-27 | 2009-06-11 | Sandoz Ag | Process for the preparation of substituted phenyl ether compounds |
| CN101263135A (zh) * | 2005-09-16 | 2008-09-10 | 艾尼纳制药公司 | 代谢调节剂和代谢相关病症的治疗 |
| US20090221639A1 (en) | 2006-04-06 | 2009-09-03 | Lisa Sarah Bertram | Heterocyclic GPCR Agonists |
| GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| AU2007334519A1 (en) | 2006-12-14 | 2008-06-26 | Merck Sharp & Dohme Corp. | Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| AU2008276057B2 (en) | 2007-07-17 | 2013-01-31 | Bristol-Myers Squibb Company | Method for modulating GPR119 G protein-coupled receptor and selected compounds |
| WO2009046416A1 (en) * | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| WO2009051119A1 (ja) | 2007-10-16 | 2009-04-23 | Daiichi Sankyo Company, Limited | ピリミジルインドリン化合物 |
| WO2009106561A1 (en) | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Pyrazine compounds for treating gpr119 related disorders |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| WO2009150144A1 (en) | 2008-06-10 | 2009-12-17 | Inovacia Ab | New gpr119modulators |
| KR101345941B1 (ko) | 2008-07-11 | 2013-12-30 | 아이알엠 엘엘씨 | Ｇｐｒ119 활성의 조절제로서의 4-페녹시메틸피페리딘 |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| WO2010075271A1 (en) * | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| EP2379542B1 (en) | 2008-12-24 | 2013-02-13 | Cadila Healthcare Limited | Novel oxime derivatives |
-
2011
- 2011-10-05 US US13/824,552 patent/US8785463B2/en not_active Expired - Fee Related
- 2011-10-05 DK DK11805633.2T patent/DK2625177T3/en active
- 2011-10-05 EP EP11805633.2A patent/EP2625177B1/en active Active
- 2011-10-05 JP JP2013532319A patent/JP5814377B2/ja not_active Expired - Fee Related
- 2011-10-05 BR BR112013007904A patent/BR112013007904A2/pt not_active IP Right Cessation
- 2011-10-05 PL PL11805633T patent/PL2625177T3/pl unknown
- 2011-10-05 KR KR1020137008931A patent/KR101563793B1/ko not_active IP Right Cessation
- 2011-10-05 ES ES11805633.2T patent/ES2551183T3/es active Active
- 2011-10-05 SG SG2013019062A patent/SG188547A1/en unknown
- 2011-10-05 WO PCT/IN2011/000694 patent/WO2012046249A1/en active Application Filing
- 2011-10-05 EA EA201390488A patent/EA022501B1/ru not_active IP Right Cessation
- 2011-10-05 MX MX2013003736A patent/MX2013003736A/es active IP Right Grant
- 2011-10-05 NZ NZ608708A patent/NZ608708A/en not_active IP Right Cessation
- 2011-10-05 AP AP2013006812A patent/AP2013006812A0/xx unknown
- 2011-10-05 AU AU2011311183A patent/AU2011311183B2/en not_active Ceased
- 2011-10-11 AR ARP110103746A patent/AR083377A1/es unknown
-
2013
- 2013-03-26 ZA ZA2013/02249A patent/ZA201302249B/en unknown
- 2013-11-27 HK HK13113263.8A patent/HK1185875A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013538870A (ja) | 2013-10-17 |
| AU2011311183A1 (en) | 2013-04-04 |
| WO2012046249A1 (en) | 2012-04-12 |
| BR112013007904A2 (pt) | 2019-09-24 |
| US8785463B2 (en) | 2014-07-22 |
| MX2013003736A (es) | 2013-05-09 |
| EA022501B1 (ru) | 2016-01-29 |
| JP5814377B2 (ja) | 2015-11-17 |
| EP2625177B1 (en) | 2015-07-29 |
| PL2625177T3 (pl) | 2015-12-31 |
| DK2625177T3 (en) | 2015-10-12 |
| KR101563793B1 (ko) | 2015-10-27 |
| EP2625177A1 (en) | 2013-08-14 |
| AP2013006812A0 (en) | 2013-04-30 |
| KR20130064801A (ko) | 2013-06-18 |
| US20130252980A1 (en) | 2013-09-26 |
| HK1185875A1 (en) | 2014-02-28 |
| EA201390488A1 (ru) | 2013-08-30 |
| AU2011311183B2 (en) | 2014-09-25 |
| NZ608708A (en) | 2015-05-29 |
| ES2551183T3 (es) | 2015-11-16 |
| SG188547A1 (en) | 2013-04-30 |
| ZA201302249B (en) | 2013-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| BR112018070956A2 (pt) | compostos da fórmula, composições farmacêuticas e métodos para distribuir um ácido nucleico para o fígado de um animal e para preparar um composto da fórmula | |
| CY1118973T1 (el) | Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων | |
| UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
| PE20151794A1 (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso | |
| FR3037957B1 (fr) | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| CY1123456T1 (el) | Μεθοδος παρασκευης οπτικως καθαρων και προαιρετικως υποκατεστημενων παραγωγων 2-(1-υδροξυ-αλκυλ)-χρωμεν-4-ονης και χρηση αυτων στην παρασκευη φαρμακευτικων ουσιων | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR094300A1 (es) | Derivados de quinolonas | |
| AR091786A1 (es) | Inhibidores de la produccion de leucotrienos | |
| AR082985A1 (es) | INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION | |
| CO6852096A2 (es) | Métodos plaguicidasque utilizan compuestos de 3-piridil tiazol sustituidos y derivados para combatir las plagas de animales i | |
| MX365744B (es) | Derivados de sulfuro de trifluoroetilo o sustituidos con n-arilamidina como acaricidas e insecticidas. | |
| RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| UY30824A1 (es) | Nuevos derivados de idazolil éster o amida, composiciones farmacéuticas conteniéndolas, procesos de preparacion y aplicaciones. | |
| MA37206B1 (fr) | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| AR070136A1 (es) | Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa | |
| AR072085A1 (es) | Compuestos triciclicos, metodos para su preparacion, composicion farma-ceutica que los comprende y su uso en el tratamiento de enfermedades me-diadas por la actividad de las proteinas quinasas | |
| BR112017001565A2 (pt) | ?composto, métodos para tratar uma infecção e para fabricar um medicamento, composição farmacêutica, e, uso de um composto? | |
| EA201700504A1 (ru) | 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение | |
| CL2013003056A1 (es) | Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas. | |
| EA201690072A1 (ru) | Состав, содержащий гиполипидемическое средство |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |